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Abstract
Background: Tuberculosis is a leading cause of death worldwide, yet the determinants of death are not well
understood. We sought to determine risk factors for mortality during treatment of drug-susceptible pulmonary
tuberculosis under program settings.
Methods: Retrospective chart review of patients with drug-susceptible tuberculosis reported to the San Francisco
Tuberculosis Control Program from 1990-2001.
Results: Of 565 patients meeting eligibility criteria, 37 (6.6%) died during the study period. Of 37 deaths, 12 (32.4%)
had tuberculosis listed as a contributing factor. In multivariate analysis controlling for follow-up time, four
characteristics were independently associated with mortality: HIV co-infection (HR = 2.57, p = 0.02), older age at
tuberculosis diagnosis (HR = 1.52 per 10 years, p = 0.001); initial sputum smear positive for acid fast bacilli
(HR = 3.07, p = 0.004); and experiencing an interruption in tuberculosis therapy (HR = 3.15, p = 0.002). The
association between treatment interruption and risk of death was due to non-adherence during the intensive
phase of treatment (HR = 3.20, p = 0.001). The median duration of treatment interruption did not differ
significantly in either intensive or continuation phases between those who died and survived (23 versus 18 days,
and 37 versus 29 days, respectively). No deaths were directly attributed to adverse drug reactions.
Conclusions: In addition to advanced age, HIV and characteristics of advanced tuberculosis, experiencing an
interruption in anti-tuberculosis therapy, primarily due to non-adherence, was also independently associated with
increased risk of death. Improving adherence early during treatment for tuberculosis may both improve
tuberculosis outcomes as well as decrease mortality.
Background
Tuberculosis is a leading cause of death worldwide.
According to the World Health Organization (WHO)
over 1.7 million people with tuberculosis died in 2008
[1]. Advanced age, male gender, delays in diagnosis and
treatment, drug resistance, and co-morbid conditions
including HIV co-infection, diabetes, renal disease and
COPD, have been associated with increased risk of
death in patients with active tuberculosis [2-8]. A sub-
stantial proportion of deaths occur during tuberculosis
treatment despite patients being on an appropriate regi-
men. Since drug-susceptible tuberculosis is a disease in
which cure is achievable in a vast majority of patients
(>95%) [9], it is plausible that the reported rate of mor-
tality of 25.8 tuberculosis deaths/100,000 person years
may be decreased if modifiable risk factors for mortality
are identified and targeted early [10]. In this retrospec-
tive study, our principle objective was to evaluate out-
comes of tuberculosis treatment in a low-incidence
setting, where patients were managed at a tuberculosis
control program without significant resource limitations.
The period during which our study was conducted pro-
vides an opportunity to evaluate outcomes not only in
HIV-uninfected patients but also a cohort of HIV-
infected patients who were HAART treatment naïve, a
population that is challenging to find in the United
States but represents more than 90% of the estimated
1.4 million HIV-infected tuberculosis cases worldwide
[1]. We previously reported our findings on risk factors
for relapse of tuberculosis [11]. The current analysis
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characteristics associated with increased risk of death
during treatment for drug-susceptible pulmonary tuber-
culosis with the aim of alerting clinicians and tuberculo-
sis control programs of characteristics that identify
groups at increased risk for mortality.
Methods
Study Population
The current study of factors associated with mortality in
drug-susceptible, pulmonary tuberculosis took advantage
of a pre-existing dataset investigating risk factors for
relapse [10]. For the parent study, we reviewed all tuber-
culosis cases reported to the San Francisco Tuberculosis
Control Program from January 1, 1990, through Decem-
ber 31, 2001. Cases with initial drug resistance and
those that were culture negative or non-cultured, with
solely extra-pulmonary disease, treated outside the
Department of Health, younger than 18 years of age,
and cases diagnosed at autopsy were excluded. The
focus of the parent study [11] was the influence of HIV
co-infection on tuberculosis outcomes. Consequently,
the parent study excluded foreign-born patients of
self-reported Asian race due to their low rate of HIV
infection compared with the general population of
tuberculosis patients in San Francisco (1.5% versus
34.8%, respectively). For the current study, medical
records were re-reviewed for additional details on ther-
apy, morbidity and mortality. Of 700 cases in the parent
study, medical records for 135 cases could not be recov-
ered. Due to incomplete data, these cases were excluded
from the final analysis. The final population for the cur-
rent study was comprised of a cohort of 565 white,
black, and US-born Asians, Pacific Islanders, Hispanic
and non-Hispanic patients with culture-positive, drug-
susceptible pulmonary tuberculosis.
Study design
The study was approved by the Committee on Human
Research of the University of California, San Francisco.
A retrospective cohort study design was used to evaluate
outcomes including mortality while on treatment for
tuberculosis. A standard data collection form was used
to record information extracted from all patient records,
including HIV serostatus, history of opportunistic infec-
tions, tuberculosis, co-morbid conditions, chest radio-
graph results, bacteriology results, treatment regimen,
use of directly observed therapy (DOT) and interrup-
tions of treatment due to non-adherence or adverse
reactions to tuberculosis medications. DOT was categor-
ized as “full” (throughout treatment) or “partial” (during
intensive phase of treatment only). San Francisco Tuber-
culosis Control Program requires treatment be initiated
under DOT for patients with any of the following
characteristics: sputum smear positive for acid fast
bacilli, suspected or confirmed drug resistant disease,
HIV co-infection, slow sputum conversion, homeless/shel-
ter resident, history of intravenous or non-intravenous
drug use, psychological disorder, alcohol abuse, history of
prior tuberculosis, and when the treating clinician deems
patient too infirm to self manage or suspects high likeli-
hood of non-adherence. Viral load and CD4
+ Tl y m p h o -
cyte counts were provided by the San Francisco AIDS
Registry. HIV status was unknown in 99 (17.5%) patients.
As part of the parent study, rigorous evaluation of the
medical records confirmed that these patients had no
identifiable risk factors for HIV [11]. All patients
received a rifamycin-based regimen for active pulmon-
ary tuberculosis approved by the American Thoracic
Society/Centers for Disease Control and Prevention/
Infectious Diseases Society of America [9]. Rifabutin
was used in place of rifampin in all patients receiving
highly active antiretroviral treatment (HAART) and
tuberculosis treatment.
Definitions
Patients were considered cured if they completed all
prescribed doses, converted their cultures to negative
and had resolution of symptoms. Treatment failure was
defined by positive cultures after 4 months of treatment
[9]. Death was defined as any death that occurred dur-
ing treatment for tuberculosis. Reported cause of death
was determined based upon review of all available
charts, death certificates and autopsy information. All
deaths listed a cause in the medical records; in addition,
35 of the 37 deaths had death certificate and/or autopsy
information. An episode of inadequate therapy was
defined as an interruption in the prescribed regimen of
any duration (prior to physician-approved treatment
completion) that resulted in fewer than three anti-tuber-
culosis medications being administered during the initial
intensive phase or fewer than two medications during
the continuation phase for either of the following: 1) an
adverse reaction to tuberculosis medications, or 2) an
episode of patient non-adherence to one or more anti-
tuberculosis medications.
All statistical analyses were performed using SAS Ver-
sion 9.1 software (SAS Institute Inc., Cary, NC). Cox
proportional-hazards regression analysis was used to
assess risk factors for mortality. The chi squared test,
Student’s t-test, and Wilcoxon rank-sum test were used
to test associations unrelated to mortality. Factors asso-
ciated with mortality in univariate analysis (p < 0.10)
were selected for a multivariate Cox proportional-
hazards regression model. CD4 cell count was missing
in 29 of 204 cases with HIV co-infection; for multivari-
ate analyses involving CD4 count, missing values were
imputed using a multiple imputation strategy [12]. All
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count run multiple times to estimate missing values.
Kaplan-Meier survival analysis was performed to com-
pare time to death by HIV status and treatment
adequacy. Survival curves were compared using the Log-
Rank test with follow-up time truncated at 18 months.
A p-value of less than 0.05 was used as a threshold for
significance.
Results
Of 565 patients meeting eligibility criteria, 37 (6.6%)
died while on treatment for tuberculosis. Sociodemo-
graphic and clinical characteristics are shown in
Table 1. In univariate analyses, patients who died during
treatment were more likely to have been older at time
of diagnosis, to have been born in the US, to have been
homeless within the year prior to tuberculosis diagnosis,
to have required hospitalization at the time of their
tuberculosis diagnosis, and to have a baseline positive
sputum smear for acid fast bacilli (all p < 0.05). HIV-
coinfection and having a history of an opportunistic
infection other than tuberculosis were also more com-
mon in the group of patients who died (all p < 0.05).
Median T-lymphocyte CD-4 count was lower at the
time of diagnosis in HIV-coinfected patients who died
during tuberculosis treatment as compared with HIV-
coinfected patients who survived (68 versus 105 respec-
tively, p = 0.06). Only one of the 24 HIV-infected
patients who died received HAART during tuberculosis
treatment; lack of HAART was highly associated with
death (HR = 5.52), but due to limited numbers, the
association did not reach statistical significance in uni-
variate analysis (p = 0.10). Treatment under direct
observation (DOT) was more commonly used in those
w h od i e d( p=0 . 0 4 ) ,h o w e v e r ,t h i sa s s o c i a t i o nw a sn o
longer significant in analyses controlling for HIV seros-
tatus and sputum smear status, a reflection of the San
Francisco Tuberculosis Control Program’s strict policy
to treat these high risk groups under DOT.
An episode of interruption in therapy from any cause
was identified in 205 of 565 study participants. Of the
205, 186 cases had an interruption in therapy that met
the study definition for inadequate therapy. Overall, 27%
of patients experienced an episode of inadequate therapy
during the intensive phase of treatment, and 23% in the
continuation phase. Experiencing an episode of inade-
quate therapy, in particular during the intensive phase,
was significantly more common in the patients who
died as compared with those who survived (p = 0.001).
Analyzed separately by the two causes defined for inade-
quate therapy, non-adherence versus adverse reactions,
the association remained significant for non-adherence
d u r i n gt h ei n t e n s i v ep h a s e( H R=3 . 2 0 ,9 5 %C I1 . 6 4 -
6.24, p = 0.001), but not for adverse reactions. While
the relative hazard was high for the association between
adverse reactions during the intensive phase and mortal-
ity, the relationship did not reach statistical significance
(HR = 1.74, 95% CI 0.73-4.13, p = 0.21). Overall, the
median duration of treatment interruption for patients
w h od i e dw a sn o td i f f e r e n tf r o mt h o s ew h os u r v i v e d
(37.5 days versus 36 days, respectively, data not shown).
Examining the median duration of days a patient
received inadequate treatment in more detail, by phases
of treatment (Table 1), we found that both intensive and
continuation phase interruptions were longer in those
who died (median of 23 and 37 days, respectively) as
compared with those who survived (median of 18 and
29 days, respectively). Whereas the association between
median duration and mortality was in a biologically
plausible direction when looked at by phases of treat-
ment, the differences were not statistically significant
(all p > 0.1).
Of the 37 deaths during treatment for tuberculosis, 12
(32.4%) had tuberculosis listed in the death certificate,
autopsy or chart either as the direct cause of or contri-
buting to cause of death, with nine of these also having
AIDS listed as a contributing factor. Of the remaining
25 deaths for which tuberculosis was not listed in the
death certificate or autopsy, 13 (35.1%) were attributed
to complications of AIDS. None of the deaths were
directly attributed to adverse drug reactions or hepato-
toxicity. In multivariate analysis, four characteristics
were independently predictive of mortality: HIV co-
infection (HR = 2.57, 95% CI 1.17-5.64, p = 0.02); older
age at diagnosis (HR = 1.52 per 10 years, 95% CI 1.18-
1.95, p = 0.001); initial sputum smear positive for acid
fast bacilli (HR = 3.07, 95% CI 1.44-6.56, p = 0.004); and
episode of inadequate tuberculosis therapy during the
intensive phase of treatment (HR = 3.15, 95% CI 1.52-
6.52, p = 0.002) (Table 2). Being born in the US was
associated with an increased risk for death, but did not
reach our predetermined level of statistical significance
(HR = 2.70, 95% CI 0.96-7.63, p = 0.06). A multivariate
analysis of HIV-infected patients was performed sepa-
rately, and five characteristics were independently pre-
dictive of mortality: history of opportunistic infection
(HR = 6.24, 95% CI 1.26-31.0, p = 0.03); lack of HAART
while on tuberculosis therapy (HR = 9.07, 95% CI 1.06-
77.4, p = 0.04); US birth (HR = 7.79, 95% CI 1.10-55.1,
p = 0.04); positive sputum smear (HR = 4.38, 95% CI
1.43-13.4, p = 0.01); and episode of inadequate therapy
during the intensive phase (HR = 3.47, 95% CI 1.27-9.50,
p = 0.02) (data not shown). CD4 cell count at the start of
therapy was included in the multivariate model, however,
its protective association was not statistically significant
(HR = 0.95 per 25 cells, 95% CI 0.84-1.06, p = 0.47).
Survival curves generated using the Kaplan-Meier
method stratified by HIV status and adequacy of
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Page 3 of 7Table 1 Sociodemographic and clinical characteristics of patients by status at end of treatment by univariate Cox
proportional-hazards regression (n = 565)
Characteristics Death during treatment
N (%)
Alive throughout treatment
N (%)
p value
N 37 528
Mean age at diagnosis ± SD 45.0 ± 16.2 40.7 ± 13.5 0.03
Median (Min-Max) 41 (22-88) 38 (18-94)
Male Gender 29 (78.4) 423 (80.1) 0.95
Race American Indian 0 9 (1.7) 0.99
African American/Black 13 (35.1) 187 (35.4) 0.97
Asian/Pacific Islander 1 (2.7) 10 (1.9) 0.73
White 23 (62.2) 322 (61.0) Ref
Hispanic ethnicity 7 (18.9) 159 (30.1) 0.16
US born 31 (83.8) 364 (68.9) 0.03
HIV positive 24 (64.9) 180 (34.1) 0.02
HAART during tuberculosis therapy 1/24 (4.2) 27/180 (15.0) 0.10
History of opportunistic infection 21/24 (87.5) 101/180 (56.1) 0.01
CD4 count
≤ 200 cells/μL
1 17/19 (89.5) 108/156 (69.2) 0.14
Median CD4 count at diagnosis (IQR)
1 68 (34-104) 105 (47-269) 0.06
Received directly observed therapy
2 Yes 28 (75.7) 251 (47.7) 0.02
Partial* 4 (10.8) 90 (17.1) 0.67
No 5 (13.5) 185 (35.2) Ref
Episode of inadequate therapeutic regimen 25 (67.6) 161 (30.5) 0.01
During intensive phase
3 24 (64.9) 129/525 (24.6) 0.001
Median duration of inadequate treatment (days) (IQR) (n = 153) 23 (6-35) 18 (9-34) 0.18
During continuation phase
4 10/33 (30.3) 116/523 (22.2) 0.44
Median duration of inadequate treatment (days) (IQR) (n = 126) 37 (24-50) 29 (13-50) 0.24
Due to non-adherence 22 (59.5) 142 (26.9) 0.01
During intensive phase
3 21 (56.8) 109/525 (20.8) 0.001
Median duration of inadequate treatment (days) (IQR) (n = 130) 8 (5-28) 15 (7-24) 0.13
During continuation phase
4 10/33 (30.3) 108/523 (20.7) 0.64
Median duration of inadequate treatment (days) (IQR) (n = 118) 30 (16-50) 29 (14-53) 0.11
Due to adverse reaction
5 10 (27.0) 49/527 (9.3) 0.10
During intensive phase
5 7 (18.9) 39/527 (7.4) 0.21
Median duration of inadequate treatment (days) (IQR) (n = 46) 29 (8-39) 14 (6-38) 0.75
During continuation phase
5 3 (8.1) 18/527 (3.4) 0.98
Median duration of inadequate treatment (days) (IQR) (n = 21) 25 (1-31) 14 (7-20) 0.40
Hospitalized for tuberculosis
6 29 (78.4) 253/526 (48.1) 0.003
Homeless within 1 year of diagnosis
7 16/27 (59.3) 138/356 (38.8) 0.04
Substance abuse at diagnosis 23 (62.2) 228 (43.2) 0.13
Sputum smear positive 27 (73.0) 233 (44.1) 0.004
Sputum culture positive 34 (91.9) 471 (89.2) 0.62
Extrapulmonary disease in addition to pulmonary disease 18 (48.7) 143 (27.1) 0.13
Cavitary disease 4 (10.8) 129 (24.4) 0.12
Any prior medical condition 25 (67.6) 288 (54.6) 0.13
1) Excluding 29 with missing data for CD4 cell count. 2) Excluding 2 with missing data for directly observed therapy. * Partial DOT = DOT used for less than the
full duration of treatment (clinicians opted to transition select patients to self-administered therapy (SAT) at the end of the intensive phase of treatment, or
initiated DOT in patients previously treated by SAT in whom clinical, radiographic or microbiologic response to treatment was delayed). 3) Excluding 3 with
missing data for intensive phase. 4) Excluding 9 with missing data for continuation phase. 5) Excluding 1 with missing data for adverse reaction. 6) Excluding 2
with missing data for hospitalization. 7) Excluding 182 with missing data for housing status.
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18 months (overall p = 0.001) are shown in Figure 1.
The greatest difference in rates of survival were between
patients with both HIV co-infection and an episode of
inadequate therapy (89.7% survival at 6 months, 81.2%
at 12 months), compared with patients with neither HIV
co-infection nor inadequate therapy (98.4% survival at 6
months, 97.1% at 12 months) (p < 0.001). Survival rates
between those with HIV co-infection and no evidence of
inadequate therapy (95.4% survival at 6 months, 94.2%
at 12 months) and those without HIV infection who had
an episode of inadequate therapy (92.6% survival at 6
and 12 months) were the same (p = 0.41).
Discussion
In this study, four characteristics were independently
associated with increased risk of mortality during treat-
ment for drug susceptible tuberculosis. These character-
istics were older age at diagnosis, HIV co-infection,
sputum smear positivity for acid fast bacilli at baseline
Table 2 Predictors of death during treatment (n = 565)
Predictors Death during
treatment
N (%)
Unadjusted
HR (95% CI),
p value
Adjusted
HR (95% CI),
p value
N 37
Mean age at diagnosis ± SD (hazard/10 year increase) 45 ± 16 1.26 (1.03-1.55), 0.03 1.52 (1.18-1.95), 0.001
Gender Male 29 (6.4) 0.98 (0.44-2.14), 0.95
Female 8 (7.1)
Ethnicity Hispanic 7 (4.2) 0.55 (0.24-1.27), 0.16
Non-Hispanic 30 (7.5)
Place of birth U.S. 31 (7.9) 2.92 (1.10-7.74), 0.03 2.70 (0.96-7.63), 0.06
Foreign 6 (3.5)
HIV status Positive 24 (11.8) 2.30 (1.14-4.61), 0.02 2.57 (1.17-5.64), 0.02
Negative/
Unknown
13 (3.6)
DOT
1 Yes/Partial* 32/373 (8.6) 2.65 (1.02-6.87), 0.04 1.31 (0.47-3.64), 0.61
No 5/190 (2.6)
Episode of inadequate therapy during intensive phase
2 Yes 24/153 (15.7) 3.39 (1.68-6.83), 0.001 3.15 (1.52-6.52), 0.002
No 13/409 (3.2)
Episode of inadequate therapy during continuation
phase
3
Yes 10/126 (7.9) 0.72 (0.32-1.65), 0.44
No 23/430 (5.4)
Sputum smear status Positive 27 (10.4) 2.97 (1.43-6.17), 0.004 3.07 (1.44-6.56), 0.004
Negative 10 (3.3)
Extrapulmonary in addition to pulmonary Yes 18 (11.2) 1.69 (0.85-3.34), 0.13
No 19 (4.7)
Cavitary disease Yes 4 (3.0) 0.43 (0.15-1.23), 0.12
No 33 (7.6)
Any prior medical condition Yes 25 (8.0) 1.74 (0.85-3.54), 0.13
No 12 (4.8)
1) Excluding 2 with missing data for directly observed therapy. * Partial DOT = DOT used for less than the full duration of treatment (clinicians opted to transition
select patients to self-administered therapy (SAT) at the end of the intensive phase of treatment, or initiated DOT in patients previously treated by SAT in whom clinical,
radiographic or microbiologic response to treatment was delayed). 2) Excluding 3 with missing data for intensive phase. 3) Excluding 9 with missing data for
continuation phase. Note-HR = hazard ratio.
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Figure 1 Kaplan-Meier survival curves showing time to death
by HIV status & treatment adequacy during the intensive
phase of therapy.
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during the intensive phase of treatment. Whereas prior
studies have reported older age, comorbid conditions
including HIV and advanced tuberculosis as non-
modifiable determinants of death in tuberculosis
[4,13-15], our study identifies treatment interruptions as
a risk factor that is potentially modifiable through pro-
grammatic action. The association is also important to
recognize as it suggests that interruptions in therapy
have implications that go beyond recognized increases
in risk for microbiologic failure, relapse of disease or
even development of drug resistance.
We sought to clarify other aspects related to interrup-
tions, including the timing, duration and cause of inter-
ruptions. The timing of inadequate therapy for
tuberculosis proved to be important. Interruptions dur-
ing the intensive phase were associated with mortality,
whereas interruptions during the continuation phase
were not. This finding suggests that interruptions occur-
ring early, when drugs have bactericidal activity against
replicating organisms, have greater implications for risk
of death than interruptions during the continuation
phase when therapy is focused on clearing persistent
bacilli to prevent relapse [16]. In regard to duration of
interruptions, the median duration was longer in those
that died as compared with those that survived, how-
ever, the difference was not statistically significant in
either intensive or continuation phases. Next, we
explored the two causes of interruptions in treatment,
adverse reactions and non-adherence, and found that
non-adherence appeared to be driving the association.
These stratified analyses may have lacked power to defi-
nitively exclude adverse reactions as a risk factor for
death, however, we believe that differences between the
two causes of interruption make this distinction plausi-
ble. In reviewing the treatment interruptions, we found
that interruptions from non-adherence often resulted in
complete cessation of all medications, in contrast to
interruptions from adverse reactions which were
handled by temporary cessation of medications followed
by swift rechallenge until a tolerable regimen was identi-
fied. We also reviewed autopsy reports, death certificates
and the medical charts for all 37 patients who died dur-
ing treatment and found no evidence to suggest that
adverse drug reactions played a direct role in any of the
deaths. Finally, it is important to note that whereas we
found non-adherence to be associated with increased
risk for death, the reverse relationship seen between
DOT use and death was due to confounding by associa-
tion given that our program has a strict policy to initiate
DOT in all patients at high risk for poor outcomes,
including death.
Our study has several limitations. Given its retrospec-
t i v en a t u r e ,w ew e r eu n a b l et od i s t i n g u i s hb e t w e e nt h e
reason for and effect of treatment interruption as it
related to the association with death. While we
reviewed all available charts, computer records, death
certificates, and autopsy information to determine
cause of death, a minority of cases had post mortem
analyses (7/37). Consequently, factors associated with
death were not necessarily causal. Second, our findings
are not relevant for HAART treated/exposed popula-
tions, as the majority of the HIV-infected individuals in
this study were HAART naive. Of the 37 deaths, only
one HIV-infected individual was on HAART, preclud-
ing our ability to evaluate the role of HAART in pre-
venting death. This is an important limitation given the
well recognized benefits of HAART on survival. How-
ever, we believe our findings are still relevant as the
majority of HIV-related tuberculosis in the world con-
tinues to be managed without early initiation of
HAART. Finally, we cannot extrapolate these findings
to foreign-born individuals who self-reported Asian
race as they were excluded from the parent study. A
recent evaluation of deaths among 7,999 culture posi-
tive pulmonary tuberculosis cases in Shanghai, China,
identified advanced age, sputum smear positivity,
comorbid conditions and gender as factors associated
with death [15]. However, additional studies are needed
to determine whether these factors also pertain to
foreign-born Asians residing in the US.
Conclusion
In summary, in addition to the nonmodifiable character-
istics of advanced age at diagnosis, HIV co-infection and
sputum smear positivity at baseline, experiencing an
interruption in treatment during the intensive phase of
treatment was associated with an increased risk of
death. Our analyses suggest that non-adherence, more
so than adverse drug reactions, may be driving this asso-
ciation. Continued investment in programs such as
DOT that can promote adherence early during treat-
ment for tuberculosis may both improve tuberculosis
outcomes as well as decrease mortality.
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